Is this you?
Request access for Pratia with your @pratia.com work email. Intera will contact you to verify and set up your account — nothing auto-publishes.
Intera lens
ICP 8Lift (cardio sample) 0.19Recruit soph 0.14
Quality Scorecard (1–100)
Overall75Recruit62Ops75Sponsor88Ther79
Performance (observed)
Historical trials
523
Completed
201
Terminated/Withdrawn
54
Completion rate
79%
Active now
260
Phase 2
168
Phase 3
314
Realized enrollment
396,433
First study year
2012
Years active
14
Match confidence
high
Enrollment velocity (inf)
28,317
Therapeutic
Areas
85% of all therapeutic areas; strong in oncology
Specialties
Oncology, multi-specialty across 85% of therapeutic areas
Breadth (conditions)
464
Languages
Multiple - German, Polish, Czech, Slovak, English, Turkish
States
8 European countries + US expansion
Recruitment (web observed)
Advertises recruitment
Yes
SEO
Y - blog and news
Capability notes
Multi-channel marketing, digital campaigns, 600+ active studies annually
Relationships
Sponsors
Merck Sharp & Dohme LLC; Pfizer; Janssen Research & Development, LLC; Eli Lilly and Company; Amgen; AbbVie
CROs
Acrotech Biopharma Inc.; Covance; Ergomed; Ergomed PLC; ICON Clinical Research; IQVIA Pty Ltd
Partnerships
100+ sites across 8 countries, expanding
Owner / parent
PE-backed; part of HUMANEVA Group; strategic growth through acquisitions
Funding
PE - Humaneva Group, Viking Global Investors ($50M + $50M option, September 2024)
Acquisitions
CRC (Czech Republic/Slovakia), P1 Trials (US early-phase oncology)
Expansion
Y - CRC acquisition (Czech/Slovakia January 2025), P1 Trials acquisition (US, December 2025)
Recent hiring
Y - acquisitions and expansion
Capacity & people
Investigators
—
Coordinators
—
CEO
Łukasz Bęczkowski
VP Site Ops
Tomasz Groń
Tech & DCT
CTMS
Proprietary in-house CTMS
eSource
Yes
Uses AI
Yes
Builds tech
Internally (CTO: Robert Mitraszewski)
Home visits
Y - at-home visits, telemedicine tools
DCT / decentralized
Y - hybrid and decentralized trial ready, telemedicine integration
Tech stack
Advanced data warehouse; proprietary technology platforms for data management
Recruiting visible
Y
Notes
Large European network with US expansion; PE-backed; tech-forward (hybrid/DCT ready); 1500+ trials since 2012; strong fit: recruitment-focused, multiple studies, innovation-oriented
Recommendation features (sample indication)
Ind fit 0.22Liftability 0.19Overall75
FUTURE MOAT: absolute enrollment rates, funnel CPR, measured SSU, screen-fail reasons.